If you are reading this please do not access this site...use http://www.unilab.com.ph instead

Products

Find by Brand Name:
A  B  C  D  E  F  G  H  I  J  K  L  M 
N  O  P  Q  R  S  T  U  V  W  X  Y  Z 
Quadtab

Rifampicin + Isoniazid + Pyrazinamide + Ethambutol HCl




Brand Name, Dosage Format and Strength
Quadtab   150 mg/ 75 mg/ 400 mg/ 275 mg Film-Coated Tablet

Therapeutic Category
Anti-infectives (Systemic)

Sub Therapeutic
Antibacterial, Antifungal, Antituberculosis, Antivirals

Class
Aminoglycoside, Cephalosporin, Chloramphenicol, Lincosamide, Macrolide, Penicillin, Penicillin + Beta lactamase Inhibitor , Penicillinase-resistant isoxazolylpenicillin, Penicillin; Beta-lactam + Beta-lactamase Inhibitor, Quinolone, Sulfonamide + Folate Inhibitor, Tetracycline, Triazole Antibiotic, Immunostimulant, Neuraminidase Inhibitor

Marketing Division





Quadtab.jpg

Rifampicin + Isoniazid + Pyrazinamide + Ethambutol HCl

Quadtab

Therapeutic Category
Anti-infectives (Systemic)
Class
Antituberculosis
Generic Name
Rifampicin + Isoniazid + Pyrazinamide + Ethambutol HCl
Brand Name, Dosage Format and Strength
Quadtab 150 mg/ 75 mg/ 400 mg/ 275 mg Film-Coated Tablet

DOSAGE AND ADMINISTRATION

The recommended anti-TB treatment regimen is based on the TB Diagnostic Category
Rifampicin + Isoniazid + Pyrazinamide + Ethambutol HCl (Quadtab) Tablet is for a 2-month initial phase treatment and should be followed by a 3-drug (e.g., Rifampicin + Isoniazid + Ethambutol HCl) or 2-drug (e.g., Rifampicin + Isoniazid), 4-month or longer continuation phase for the treatment of tuberculosis. Continue treatment if patient is still sputum or culture positive, or if resistant organisms are present.
 
Usual Adult Dose: Orally, once daily, either 1 hr before or 2 hrs after a meal.
Patient’s Body Weight (kg)
Once Daily Dose
30 to 39
2 tabs
40 to 54
3 tabs
55 to 70
4 tabs
71 and higher
5 tabs
                                                  
Recommended Dosing for Essential Antituberculosis Drugs
 
Drugs
Dosage (mg/kg body weight)
Daily
3 times weekly
Isoniazid (H)
5 (range: 4 to 6)
Daily maximum: 300 mg
10 (range: 8 to 12)
Rifampicin (R)
10 (range: 8 to 12)
Daily maximum: 600 mg
10 (range: 8 to 12)
Daily maximum: 600 mg
Pyrazinamide (Z)
25 (range: 20 to 30)
35 (range: 30 to 40)
Ethambutol HCl (E)
15 (range: 15 to 25)
30 (range: 20 to 35)
Streptomycin (S)
15 (range: 12 to 18)
15 (range: 12 to 18)

                             Recommended Treatment Regimens for each Diagnostic Category

                                           (adapted from the WHO Treatment of Tuberculosis:

                         Guidelines for National Programmes, 3rd Edition, revised Chapter 4 June 2004)

TB Diagnostic Category

TB Patients

TB Treatment regimens i

Initial phase

Continuation phase

 

I

 

New smear-positive patients;

New smear-negative PTB with extensive parenchymal involvement;

Concomitant HIV disease or severe forms of EPTB ii

Preferred

2 HRZE iii

Preferred

4 HR

4 (HR)3

Optional

2 (HRZE)3

or

2 HRZE iv

Optional

4 (HR)3

or

6 HE v

 

II

 

Previously treated sputum smear-positive PTB:

  • Relapse;
  • Reatment after default

 

Preferred

2 HRZES /

1 HRZE vi

Preferred

5 HRE vi

Optional

2 (HRZES)3 /

1 HRZE3

Optional

5 (HRE)3

  • Treatment failure Category I vii

 

In settings with:

  • Adequate program performance;
  • Representative DRS data showing high rates of MDR TB and/or capacity for DST of cases;
  • Availability of Category IV regimens

Specially designed standardized or individualized regimens are often needed for these patients

In settings where

  • Representative DRS data show low rates of MDR TB or individualized DST shows drug-susceptible disease

or

In settings of

  • Poor program performance;
  • Absence of representative DRS data;
  • Insufficient resources to implement Category IV treatment

Preferred

2 HRZES /

1 HRZE

Preferred

5 HRE vi

Optional

2 (HRZES)3 /

1 HRZE3

Optional

5 (HRE)3

 

III

 

New smear-negative PTB (other than Category I) and less severe forms of EPTB

Preferred

2 HRZE viii

Preferred

4 HR

4 (HR)3

Optional

2 (HRZE)3

or

2 HRZE

Optional

4 (HR)3

or

6 HE

 

IV

 

Chronic (still sputum-positive after supervised re-treatment ); proven or suspected MDR TB cases ix

Specially designed standardized or individualized regimens

i Numbers preceding regimens indicate length of treatment (months).  Subscripts following regimens indicate frequency of administration (days per week).  When no subscripts are given, the regimen is daily.  Direct observation of drug intake is always required during the initial phase of treatment and strongly recommended when Rifampicin is used in the continuation phase and required when treatment is given intermittently.  FDCs are highly recommended for use in both the initial and continuation phases of treatment.
ii Severe forms of EPTB are the following: meningeal, pericardial, peritoneal, bilateral or extensive pleural effusive, spinal, intestinal, and genitourinary.
iii Streptomycin may be used instead of ethambutol.  In tuberculous meningitis, ethambutol should be replaced by streptomycin.
iv Intermittent initial phase therapy is not recommended when the continuation phase of isoniazid and ethambutol is used.
v This regimen may be considered in situations where the preferred regimen cannot be applied as recommended.  However, it is associated with a higher rate of treatment failure and relapse compared with the 4 HR continuation phase regimen.  Intermittent initial phase treatment is not recommended when followed by the 6 HE continuation phase regimen.
vi Daily treatment is preferred.  However, thrice weekly treatment during the continuation phase or during both phases is an acceptable option.
vii Treatment failures may be at risk of MDR TB, particularly if rifampicin was used in the continuation phase.  Drug susceptibility testing is recommended for these cases if available.  Treatment failures with known or suspected MDR TB should be treated with a Category IV regimen.
viii Ethambutol in the initial phase may be omitted for patients with limited, non-cavitary, smear-negative pulmonary TB who are known to be HIV-negative, patients with less severe forms of extrapulmonary TB, and young children with primary TB.
ix Drug susceptibility testing is recommended for patients who are contacts of MDR TB patients.

Legend:

PTB – Pulmonary Tuberculosis

HIV – Human Immunodeficiency Virus

EPTB – Extrapulmonary Tuberculosis

DRS – Drug-Resistance Surveillance

MDR-TB – Multidrug-resistant Tuberculosis

DST – Individualized Susceptibility Testing

FDC – Fixed-Dose Combination

Patient Information 

  • Take medication on regular basis; avoid missing doses. Do not discontinue therapy except on advice of physician.
  • Medication may cause a reddish-orange discoloration of the urine, stools, saliva, tears, sweat and sputum.  This is to be expected and is not harmful.  Soft contact lenses may be permanently stained.
  • Notify physician promptly if any of the following symptoms are experienced: fever, loss of appetite, malaise, nausea and vomiting, darkened urine, yellowish discoloration of the skin and eyes, pain or swelling of the joints.

Already Registered?

Remember Me

I forgot my username & password